Lexiscan (regadenoson) Disease Interactions
There are 6 disease interactions with Lexiscan (regadenoson):
Regadenoson (Includes Lexiscan) ↔ MI
Severe Potential Hazard, Moderate plausibility. Applies to: Ischemic Heart Disease
The use of regadenoson has been associated with fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest. Therapy with regadenoson should be avoided in patients with symptoms or signs of acute myocardial ischemia, such as unstable angina or cardiovascular instability as these patients may be at greater risk of serious cardiovascular reactions. Appropriate monitoring and equipment for resuscitation should be available before administering regadenoson. If serious reactions to regadenoson occur, consider the use of aminophylline, an adenosine antagonist, to shorten the duration of increased coronary blood flow induced by regadenoson administration.
Regadenoson (Includes Lexiscan) ↔ sinus/AV node dysfunction
Severe Potential Hazard, High plausibility. Applies to: Heart Block
The use of regadenoson is contraindicated in patients with second- or third- degree AV block, or with sinus node dysfunction in the absence of a functional artificial pacemaker. Adenosine receptor agonists, including regadenoson, can depress the SA and AV nodes and may cause first-, second- or third-degree AV block, or sinus bradycardia requiring intervention.
Regadenoson (Includes Lexiscan) ↔ arrhythmias
Moderate Potential Hazard, Moderate plausibility. Applies to: Arrhythmias
New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter, and cardiac arrest have occurred following regadenoson injection. Therapy with regadenoson should be administered cautiously in patients with cardiac conduction disorders.
Regadenoson (Includes Lexiscan) ↔ COPD/asthma
Moderate Potential Hazard, Moderate plausibility. Applies to: Asthma, Chronic Obstructive Pulmonary Disease
The use of regadenoson, as others adenosine receptor agonist may induce dyspnea, bronchoconstriction and respiratory compromise in patients with COPD or asthma. Appropriate bronchodilator therapy and resuscitative measures should be available prior to regadenoson administration.
Regadenoson (Includes Lexiscan) ↔ hypotension
Moderate Potential Hazard, Moderate plausibility. Applies to: Valvular Heart Disease, Pericarditis, Cerebrovascular Insufficiency
The use of adenosine receptor agonists, including regadenoson, has been associated with arterial vasodilation and hypotension. The risk of serious hypotension may be higher in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, stenotic valvular heart disease, pericarditis or pericardial effusions, or stenotic carotid artery disease with cerebrovascular insufficiency.
Regadenoson (Includes Lexiscan) ↔ seizures
Moderate Potential Hazard, Moderate plausibility. Applies to: Seizures
The use of regadenoson may lower the seizure threshold. New-onset or recurrence of convulsive seizures has occurred following regadenoson injection. Caution is recommended when using this agent in patients with or predisposition to seizure disorders.
Lexiscan (regadenoson) drug interactions
There are 49 drug interactions with Lexiscan (regadenoson)
Lexiscan (regadenoson) alcohol/food interactions
There are 2 alcohol/food interactions with Lexiscan (regadenoson)
More about Lexiscan (regadenoson)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Compare Alternatives
- Pricing & Coupons
- En Español
- 14 Reviews
- Drug class: cardiac stressing agents
- FDA Alerts (1)
- FDA Approval History
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No interaction information available.|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.